Suspended | Phase II
A phase II study of tazemetostat (EPZ-6438) (IND#138671) in recurrent or persistent endometrioid or clear cell carcinoma of the ovary, and recurrent or persistent endometrioid endometrial adenocarcinoma.
To find out if this approach is better or worse than the usual approach for your ovarian or endometrial cancer.
- Tazemetostat 800 mg (4 tablets by mouth two times a day) until disease progression or unacceptable toxicity.
- Patients must keep a pill diary.
Patients will be followed every 3 months for 2 years and then every 6 months for 3 years (5 years total).
Key Participation Requirements:
19 years and older
Pathologically proven diagnosis of recurrent or persistent ovarian endometrioid or clear cell carcinoma, OR recurrent or persistent endometrioid endometrial adenocarcinoma.
Patients must have completed prior therapy anywhere from 14 days to 6 weeks before registration depending on which therapy regimen was assigned.
Patients must sign an approved informed consent and authorization permitting release of personal health information.
Methodist Health System Trial Code:
For more information, visit the U.S. National Library of Medicine clinical trial database.